证券代码：600252 证券简称：中恒集团 公告编号：临2025-58 广西梧州中恒集团股份有限公司 第十届监事会第十五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）第十届监事会第十五次会议通知和议 案材料于2025年6月11日以电子邮件的方式发出，会议于2025年6月13日以通讯方式召开。会议应参加表 决监事3人，实际参加表决监事3人。会议的召集和召开符合《公司法》《公司章程》和《公司监事会议 事规则》的有关规定。 二、监事会会议审议情况 会议审议并以记名投票方式表决通过：《广西梧州中恒集团股份有限公司关于资产损失财务核销的议 案》。 本次拟核销的存货以及固定资产原值1,789,961.56元，预计损失978,888.18元，其中影响2024年度利润总 额为825,135.58元，本次财务核销事项所产生的影响已计入2024年度及以前年度的损益，根据会计准 则，该事项不会对公司2025年度损益产生影响。 特此公告。 广西梧州 ...

股票代码：600381 股票简称：*ST春天 公告编号：2025-029 青海春天药用资源科技股份有限公司 第九届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 青海春天药用资源科技股份有限公司（以下简称"公司"）董事会于2025年6月16日上午10：00时在青海 省西宁市城北区生物园区经二路12号公司会议室，以现场表决结合通讯表决的形式召开。本次会议应到 董事7人，实际到会董事7人。会议由公司董事长张雪峰先生主持，公司监事、高级管理人员列席。本次 会议的召集、召开及表决方式符合《公司法》及《公司章程》等的有关规定，所形成决议合法有效。 二、董事会会议审议情况 经与会董事认真审议，本次会议审议通过了如下议案： 1.《关于追认日常关联交易暨公司2025年度日常关联交易预计的议案》 本议案经公司独立董事专门会议审议通过并同意提交公司董事会审议。关联董事张雪峰已回避本《议 案》的表决。 表决情况：6票同意，0票反对，0票弃权。 本议案需提交公司股东会审议，详情请见公司2025-03 ...

证券代码：603083 证券简称：剑桥科技 公告编号：临2025-037 上海剑桥科技股份有限公司 2025年第一次临时股东大会决议公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025年6月16日 (二)股东大会召开的地点：上海市闵行区浦星公路800号A栋上海浦江智选假日酒店多功能厅 1.00、议案名称：关于减少注册资本、取消监事会并修订现行《公司章程》及相关治理制度的议案 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，股东大会主持情况等 本次会议由公司董事会召集，经董事长Gerald G Wong先生提议和半数以上董事共同推举，本次会议由 董事赵宏伟先生主持，以现场投票与网络投票相结合的方式表决。会议的召集和召开、出席会议的股东 人数及表决方式均符合《公司法》《证券法》和《公司章程》的有关规定。公司聘请的德恒上海律师事 务所指派 ...

尊敬的投资者: 为进一步优化网点布局,我公司将撤销申万宏源证券有限公司宁波大榭信拓路证券营业部(以下简称"申万宏源证券 宁波大榭信拓路营业部"),届时位于浙江省宁波市大榭开发区信拓路168号海华楼A座111室、410室的经营场所将予 以关闭并停止营业。为保障您证券交易、资金划转的正常进行,现将相关事项公告如下: 一、申万宏源证券宁波大榭信拓路营业部客户将整体迁移至申万宏源证券有限公司宁波泰康中路证券营业部(以下 简称"申万宏源证券宁波泰康中路营业部")。整体迁移完成后,您将直接转变成为申万宏源证券宁波泰康中路营业部 客户,由该营业部为您提供后续服务。迁移后您的资金账号、交易密码和资金密码不变,您原先使用的交易方式及交 易软件等保持不变,您的证券交易及资金划转不受任何影响。 二、如果您不同意迁移成为申万宏源证券宁波泰康中路营业部客户,请自本公告发布之日起三个工作日内，携带本 人有效身份证明文件至申万宏源证券各营业部网点通柜办理销户及撤销指定、转托管等手续。网上开户的客户亦 可通过网上办理销户手续,详情请拨打95523咨询。 三、逾期未办理销户及撤销指定、转托管手续的客户,我公司视同您同意整体迁移成为申万宏源证券 ...

Group 1 - The core viewpoint of the articles highlights the strong demand for Haitian Flavor Industry's IPO, with a subscription amount reaching nearly 400 billion HKD, oversubscribed by approximately 695 times compared to the initial fundraising target of 573 million HKD [2] - The company plans to fully exercise its over-allotment option, increasing the share issuance by 6%, with a final offer price set at 36.3 HKD, leading to an expected total fundraising amount of about 10.15 billion HKD [2] - The international offering attracted significant interest from top institutional investors, with cornerstone investors collectively subscribing for nearly 1.29 million shares, accounting for nearly 50% of the total shares offered, amounting to nearly 4.7 billion HKD [2] Group 2 - Haitian Flavor Industry is set to officially list on the Hong Kong Stock Exchange on June 19, reflecting strong global investor confidence in the Chinese consumer market and the core competitiveness of leading companies in the seasoning industry [3] - The Hong Kong IPO market has shown strong attractiveness this year, with 29 companies completing listings in the first five months, accumulating a total fundraising amount of 77.7 billion HKD, making it the leading market globally in terms of fundraising [3] - There is an expectation for many quality companies to continue listing in Hong Kong in the second half of the year, with consumer and technology sectors remaining focal points for investors [3]

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. has received approval for the registration of Fumaric Acid Quetiapine Sustained-Release Tablets, enhancing its product line in the treatment of mental disorders and increasing market competitiveness [2] Group 1: Product Approvals and Market Potential - The Fumaric Acid Quetiapine Sustained-Release Tablets are developed by AstraZeneca and are primarily used for treating schizophrenia and depressive episodes in bipolar disorder, with a projected domestic market sales of approximately 451 million yuan in 2024 [2] - Huahai Pharmaceutical has recently received multiple drug approvals, indicating strong R&D capabilities and pipeline efficiency, including Dagagliflozin Metformin Sustained-Release Tablets and Tolvaptan Tablets, with projected sales of approximately 195 million yuan and 497 million yuan respectively in 2024 [2] Group 2: Business Growth and Revenue - The formulation business is becoming a growth engine for Huahai Pharmaceutical, with revenue expected to increase from 4.721 billion yuan in 2022 to 5.759 billion yuan in 2024, raising its revenue share from 57.11% to 60.32% [3] - The company has 105 formulation products approved by the US ANDA and 79 products approved by the National Medical Products Administration, covering various therapeutic areas including cardiovascular, mental disorders, and infections [3] Group 3: Strategic Initiatives and Innovations - Huahai Pharmaceutical is committed to advancing its biological innovation drug strategy, with significant investments in R&D for innovative drugs, particularly in oncology and autoimmune diseases [4] - The company’s subsidiary, Shanghai Huatai Biological Pharmaceutical Co., Ltd., is preparing to submit an ANDA for its HB0034 project, aimed at treating generalized pustular psoriasis, with expected approval next year [4]

Core Viewpoint - The company emphasizes its commitment to fresh and healthy products, aiming to cater to consumer needs and trends while expanding its brand offerings and services [1] Group 1: Financial Performance - In 2023, the company achieved a revenue of 2.751 billion yuan, representing a year-on-year increase of 4.09% [1] - The net profit attributable to shareholders was 28.9438 million yuan, showing a significant growth of 30.16% year-on-year [1] - For the first quarter of 2025, the company reported a revenue of 654 million yuan, a year-on-year increase of 1.75% [3] - The net profit attributable to shareholders for the same period was 13.3067 million yuan, reflecting a growth of 28.38% year-on-year [3] Group 2: Store Operations - As of the first quarter of 2025, the company had a total of 1,897 operating stores, including 1,407 franchise stores and 490 direct stores, with 10 signed but not yet opened [2] - The number of operating stores decreased by 71 compared to 2024, primarily due to a strategy focused on quality over quantity, leading to the closure of underperforming stores [2] Group 3: Product Strategy - The company is implementing a large product strategy based on consumer scenarios, with its "Jiuanshan Milk" topping sales on the Tmall platform from May to June 2024 [3] - The company is exploring new business models, including "milk bar + light dining," and expanding product lines such as pizza and coffee, which are gaining recognition among young consumers and white-collar workers [3] - The "Thick Pizza" and "Yicheng Coffee" brands are being developed as strategic extensions, with "Thick Pizza" available in approximately 400 stores and "Yicheng Coffee" in 105 milk bar locations [3] Group 4: Future Outlook - The company aims to become the leading brand in China's milk bar chain and a leader in fresh and healthy food, focusing on core products like Jiuanshan Milk, organic milk, and functional baked goods to drive long-term revenue growth [4]

Core Viewpoint - The company, Guang'an Aizhong, is undergoing a strategic transformation to focus on four major industry brands: "Aizhong Public Utility," "Aizhong Green Energy," "Aizhong Modern Services," and "Aizhong Capital" in response to the global trend of energy transformation towards green and low-carbon services [2][6]. Group 1: Public Utility Sector - Guang'an Aizhong operates 10 water plants, 7 gas storage and distribution stations, 8 gas distribution stations, 2 CNG refueling stations, 12 110kV substations, 21 35kV substations, and 12 hydropower stations with a total installed capacity of 436,400 kW, an annual water supply capacity of 117 million cubic meters, and an annual gas supply capacity of 980 million cubic meters, serving approximately 2.4 million customers [3][4]. - The company aims to enhance the quality of its water, electricity, and gas services through digital empowerment and smart operations, ensuring a solid foundation for its transformation [3][4]. - The "multi-meter integration" project has achieved international advanced levels, allowing for a comprehensive energy management model that is replicable and scalable [4]. Group 2: Modern Services - Guang'an Aizhong is expanding into the modern services sector by leveraging technology to enhance customer value, focusing on both C-end household services and B-end industrial services [5]. - The company aims to explore value from 2 million categorized customers and 1.2 million terminal customers, enhancing brand and market value [5]. Group 3: Green Energy Development - The company is actively transitioning to the green energy sector, focusing on hydropower and expanding into photovoltaic energy to meet the growing demand for green energy [6]. - Guang'an Aizhong's strategy includes establishing distributed photovoltaic power stations and centralized photovoltaic power stations in advantageous regions, as well as acquiring quality renewable energy assets through "Aizhong Capital" [6]. Group 4: Future Development - The company plans to explore virtual power plants and leverage its unique advantages for future development in line with the requirements of a new power system [7].

6月16日，"香港智能机器人发展前景论坛暨港仔机器人具身智能品牌战略启幕式"活动在香港科学园隆 重举行。活动现场上，由港仔机器人(00370.HK)与全球领先的云端机器人运营商达闼机器人强强联合， 合资成立的香港仔机器人有限公司，首次向全球展示香港本土具身智能人形机器人的创新成果。 香港特区政府财经事务及库务局副局长陈浩濂出席论坛并致辞，其表示，香港特区政府一直十分重视人 工智能与机器人技术的发展，政府也通过创科产业引导基金及一系列工业资助计划，包括"新型工业加 速计划"和"新型工业化资助计划"，积极支持企业在港发展智能制造和先进技术应用，推动本地工业向 高增值化和智能化迈进，加快创科成果的商品化和产业化。 根据不同的应用场景，港仔机器人在活动现场和密集发布了一系列新品机器人，包括最贴心的人形机器 人Cloud Ginger、载荷最大的智能巡逻机器人Cloud Ranger、关节数最多的人形机器人公版机Cloud Buddy等，特别是，5台Cloud Ginger机器人在歌曲《东方之珠》伴奏下起舞，赢得现场嘉宾的一致赞 叹。同时，港仔机器人举行了战略合作签约仪式，分别与美年健康（002044）、丰盛生活服务、 ...

对于证券简称变更的原因，韦尔股份在公告中阐述，公司于2019年完成了对全球前三大图像传感器芯片 设计公司豪威科技的收购，逐步构建了图像传感器解决方案、显示解决方案和模拟解决方案三大业务体 系。2024年公司半导体设计业务中，公司图像传感器解决方案业务实现营业收入191.90亿元，占主营业 务收入的比例为74.76%。同时，根据公司目前主营产品品牌影响力及产品类型占比，变更公司名称、 证券简称能够更加全面地体现公司的产业布局和实际情况，准确反映公司未来战略发展方向，便于集团 化管理及精细化管控，进一步发挥公司品牌效应及品牌优势，提升市场影响力，同时增加投资者对公司 业务情况的理解和投资判断。 6月16日晚间，韦尔股份公告称，经公司申请，并经上交所办理，公司证券简称将于6月20日起由"韦尔 股份"变更为"豪威集团"，公司证券代码"603501"保持不变。 据披露，公司此前于5月19日召开董事会会议，审议通过了《关于变更公司名称及证券简称的议案》， 该事项已经公司于6月10日召开的2024年年度股东大会审议通过。 近日，公司已完成工商变更登记等相关手续，并取得了上海市市场监督管理局换发的《营业执照》，公 司名称正式 ...